The United Kingdom is a global leader in pharmaceutical research, manufacturing, and clinical development. With world-renowned institutions, a strong healthcare infrastructure, and a science-friendly regulatory environment, the UK is a top destination for pharmaceutical companies seeking to launch, manufacture, or distribute products.
However, entering or expanding within the UK market requires strict adherence to licensing regulations enforced by bodies such as the Medicines and Healthcare products Regulatory Agency (MHRA). Whether you’re a multinational launching a UK branch or a growing biotech scaling production, securing the right licences—and compliant operational premises—is essential.
Fraser Bond supports pharmaceutical companies by facilitating access to fully licensed, regulation-ready commercial spaces and by working alongside regulatory consultants to streamline market entry and growth.
The MHRA is the UK’s regulator for medicines, medical devices, and clinical trials. Licences include:
Manufacturer’s Licence (MIA/MHRA) – Required for manufacturing or assembling human-use medicines.
Wholesale Dealer’s Licence (WDA(H)) – For importing, storing, and distributing medicinal products.
Clinical Trial Authorisation (CTA) – Required to conduct human clinical trials.
Marketing Authorisation (MA) – Approval to sell or supply a medicine in the UK.
Each licence involves detailed inspections, robust documentation, and location-specific infrastructure requirements.
If your products involve controlled substances, you may require additional Home Office licences under the Misuse of Drugs Regulations 2001.
MHRA licencing requires facilities to meet strict standards around temperature control, hygiene, security, and segregation.
Pharmaceutical premises must comply with GMP or Good Distribution Practice (GDP) depending on their function. These standards are assessed during regulatory inspections.
Applicants must demonstrate that their location is appropriately equipped and documented before a licence is granted. This includes proof of lease or ownership and layout plans.
Fraser Bond plays a strategic role in supporting pharmaceutical firms through location readiness, property compliance, and real estate strategy. Here’s how:
We source properties that meet the infrastructure and security requirements of MHRA inspections—including cleanroom potential, cold chain support, and warehouse standards.
We advise on local planning permissions, use class restrictions, and proximity to research hubs or logistics corridors (e.g., Cambridge, Stevenage, or Heathrow).
We help prepare supporting documentation required during licence applications, including layout approvals, lease summaries, and landlord agreements.
Fraser Bond partners with specialist licensing consultants and GMP advisors to deliver an end-to-end licensing support ecosystem.
Foreign pharmaceutical companies entering the UK often face challenges related to:
Understanding MHRA protocols
Converting non-UK GMP certification
Securing compliant premises and warehouse capacity
Aligning operations with post-Brexit trade and customs rules
Fraser Bond mitigates these barriers by providing local expertise, secure premises, and specialist partnerships.
Licensing is the foundation of compliant pharmaceutical operations in the UK. Whether launching clinical trials, setting up a distribution centre, or opening a GMP facility, pharmaceutical firms must align with MHRA, Home Office, and local regulatory frameworks.
Fraser Bond enables success by offering regulatory-ready property solutions tailored to the pharmaceutical sector. Our services support faster licencing, reduced risk, and seamless operational launches—ensuring that your facilities meet not only legal standards but industry best practices.
